Clinicopathological Characteristics and Prognostic Profiles of Breast Carcinoma with Neuroendocrine Features

Abstract

Background: Breast carcinoma with neuroendocrine features includes neuroendocrine neoplasm of the breast and invasive breast cancer with neuroendocrine differentiation. This study aimed to investigate the clinicopathological features and prognosis of this disease according to the fifth edition of the World Health Organization classification of breast tumors. Materials and Methods: A total of 87 patients with breast carcinoma with neuroendocrine features treated in the First Medical Center, Chinese PLA General Hospital from January 2001 to January 2022 were retrospectively enrolled in this study. Results: More than half of the patients were postmenopausal patients, especially those with neuroendocrine neoplasm (62.96%). There were more patients with human epidermal growth factor receptor 2 negative and hormone receptor positive tumors, and most of them were Luminal B type (71.26%). The multivariate analysis showed that diabetes and stage IV disease were related to the progression-free survival of breast carcinoma with neuroendocrine features patients (p = 0.004 and p < 0.001, respectively). Conclusion: Breast carcinoma with neuroendocrine features tended to be human epidermal growth factor receptor 2 negative and hormone receptor positive tumors, most of them were Luminal B type, and the related factors of progression-free survival were diabetes and stage IV disease.

Bridging Discoveries and Treatments: The New Landscape of Breast Cancer Research

“…“Clinicopathological Characteristics and Prognostic Profiles of Breast Carcinoma with Neuroendocrine Features” examined the clinicopathological characteristics and prognostic outcomes of breast carcinoma with neuroendocrine features [ 1 ]. This study found that these tumors are generally hormone receptor-positive and have a higher prevalence among postmenopausal women.…”

“…Welcome to our Special Issue, “Advances in Breast Cancer Research and Treatment” of Life , where we have embarked on a comprehensive exploration of groundbreaking studies that advance our understanding and management of breast cancer. Each paper contributes uniquely to the evolving landscape of breast cancer research, ranging from the clinicopathological characteristics of breast carcinoma with neuroendocrine features [ 1 ], the identification of hub genes in the context of non-alcoholic fatty liver disease and triple-negative breast cancer [ 2 ], to advancements in diagnostic techniques [ 3 ], and the exploration of immunotherapy biomarkers [ 4 ]. Some of the topics covered include innovative methods for breast cancer classification combining transfer learning and attention mechanisms [ 5 ] and the role of diffusion-weighted imaging in breast cancer diagnosis among young patients [ 6 ].…”